bioAffinity Technologies Closes $3.2 Million Public Offering
bioAffinity Technologies, Inc., a biotechnology company focused on noninvasive lung cancer detection tests, has closed its public offering for $3.2 million in gross proceeds before fees and expenses. The offering included the sale of 4 million shares at $0.80 per share.
Tickers: $BIAF